“The most promising of these, developed by Wuhan-based Sinopharm, is already being given to frontline workers in the United Arab Emirates. According to Wu Guizhen, chief biosafety expert at the Chinese Center for Disease Control and Prevention, Sinopharm’s candidate is on track for full approval this month or next.”
Sinopharm has experience with WHO pre-qualification for vaccines. Hence, it should be an issue obtaining WHO pre-qualification for Sinopharm Covid Vaccine.
"Sinopharm and Sinovac both have other vaccines pre-qualified by the WHO. A subsidiary of Sinopharm was the first to receive WHO prequalification for Japanese encephalitis vaccines after years of support from several UN agencies to help it meet the standard. “They know what the WHO wants,” Kim said, adding that China was supplying 80 per cent of the Japanese encephalitis vaccines in Asia."
Tengku Zafrul added that to encourage Malaysians to get preventive vaccinations to curb the spread of diseases, the government would also expand the scope of tax exemption for the medical treatment covering vaccination expenses such as pneumococcal, influenza and Covid-19.
He also said tax exemption would be given for the vaccination cost for personal, spouse and children with a limit up to RM1,000.
Rakuten Trade upgrades HWGB price target to push for RM1.52 near term!
• The announcement of its JV co obtaining approval from U.S. Food and Drug Administration to conduct clinical trial phase IV for Covid-19 vaccine is expected to generate interest in the stock and see it retest its all-time high record. • From here, resistance levels are seen at RM0.96 (R1) and RM1.16 (R2) level.
@Savvy88 No need to worry at all. There is no evidence.
“ No reason to say mink-related coronavirus mutation will harm vaccine development: WHO Europe chief
On Friday, experts from the Geneva-based WHO also said that there is no evidence at the moment that the mutation of SARS-CoV-2 virus in minks in Denmark will affect the efficacy of future vaccines for COVID-19.”
Gloves producers and Pharma healthcare are the main beneficiaries { budget 2021 } no windfall tax good for glove producers especially the second tiers. 10 years tax incentives for pharma and healthcare companies producing vaccines
For vaccine related, potential beneficiaries may include pharmaceutical companies such as PHARMA (NR), DPHARMA (NR), BINTAI (NR), SOLUTN (NR) and HWGB (NR).
"Denmark, in an unfortunate decision, has decided to kill every mink in the country to stop the spread of mutated coronavirus to humans. The total estimated population of minks in Denmark is around 15 million.
Danish Prime Minister Mette Frederiksen made the decision public on November 4, 2020. He acknowledged that it was a “heavy decision” but the situation required “resolute action.”
OTHERS PT HO WAH GENTING (PT HWG), A WHOLLY-OWNED SUBSIDIARY OF HWGB, OBTAINED APPROVAL FROM MINISTRY OF HEALTH OF INDONESIA (MOH INDONESIA) (KEMENTERIAN KESEHATAN REPUBLIK INDONESIA) FOR MEDICAL DEVICES
The Board of Directors is pleased to announce that PT HWG had today obtained approval from MOH Indonesia to manufacture surgical face masks, COVID-19 rapid test cassettes and liquid chemical sterilants / high level disinfectants subject to the following conditions:
Production under the supervision of Ariston Ginting, being the registered pharmacist of PT HWG at all times;
To apply Guidelines of Good Manufacturing Practices for Medical Devices in terms of the facilities documentation and hygiene sanitation;
To furnish yearly production result report to the Director General of the Pharmacy and Medical Devices, copied to the provincial and district health office by location;
Testing its products by an accredited or approved laboratory for carrying out analysis and inspection on the production material used and the final product; and
Carry out the production of medical peripheral equipment in accordance with the regulation of Ministry of Health No. 1189/MENKES/PER/VIII/2010, in relation to the production of medical devices and household health supplies and other related regulations.
The approval is valid for (1) one year and it is compulsory for PT HWG to comply with the statutory provisions. Any amendments deemed appropriate has to be made within the stipulated timeframe.
Add the latest news on approval to manufacture medical devices plus the earlier news on manufacturing pharmaceutical products we should start to see strong uptrend with HWGB towards their TP of 3.0.
And I am sure the glove players will move over to vaccine counters now. So once the selling off is done there vaccine counters will rise quicker with the added funds.
Efficacy of Sinopharm vaccine is higher than Pfizer vaccine. Sinopharm vaccine showed 100% efficacy while Pfizer vaccine only showed 90% efficacy.
-----------
US drug maker Pfizer said its mRNA vaccine candidate is more than 90 percent effective, while SINOPHARM's inactivated vaccine SHOWED 100 PERCENT efficacy at one case in Mexico, both are promising results and have brought about hope of wider use in the fight against the coronavirus, experts said.
Pfizer's announcement got world's attention and many news outlets reported it with enthusiasm, but Sinopharm's vaccine, which have been used on 56,000 people who have traveled abroad, none of whom became infected, were challenged by many Western media when the data was released.
The different reaction revealed Western media's double standard on vaccines for China and the US, with an aim to politicize the issue, Chinese experts said.
Pfizer's 90 percent was based on phase III clinical trials while Sinopharm's is based on observation after emergency use. Although the former has greater authority academically, the latter is also a control study, Tao further explained, noting that the fact 56,000 people did not get infected could serve as a reference for the vaccine's efficacy.
But a major challenge for mRNA vaccines is the temperature requirement for storage - minus 70C for long-term stability in comparison to 2-8 C for the majority of other types of vaccine, Tao noted, "Storage and transportation will be very expensive."
SUICIDE halts Brazil trial of Chinese vaccine attacked by Bolsonaro
The trial’s organizers criticized Anvisa’s decision, saying they had not been notified in advance and that there was no reason to stop the trial.
Although a trial volunteer had died, it had nothing to do with the vaccine, Jean Gorinchteyn, Health Secretary for the state of Sao Paulo told a news conference on Tuesday.
“We had an external event that led to the regulator being notified,” Gorinchteyn said. “This vaccine is safe.”
Dimas Covas, the head of Sao Paulo’s medical research institute Butantan, which is conducting the Sinovac trial, said the vaccine had shown no serious adverse effects. Speaking at the same news conference, he said he hoped the trial would be resumed later on Tuesday or Wednesday.
Anvisa said the initial information it received from Butantan had not specified that the death was a SUICIDE.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
NPRA1985
3,415 posts
Posted by NPRA1985 > 2020-11-07 01:44 | Report Abuse
“The most promising of these, developed by Wuhan-based Sinopharm, is already being given to frontline workers in the United Arab Emirates. According to Wu Guizhen, chief biosafety expert at the Chinese Center for Disease Control and Prevention, Sinopharm’s candidate is on track for full approval this month or next.”
https://www.foreignaffairs.com/articles/united-states/2020-11-05/china-winning-vaccine-race?amp=true